MedTrace Logo

Safety and Efficacy Study of EVO101 Topical Cream in Atopic Dermatitis

NCT05579899 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 119

Last updated 2025-03-05

Study results available
· View outcomes & findings →

Summary

This is a Phase 2a safety and efficacy study of EVO101 for the treatment of adults with atopic dermatitis

Conditions

  • Atopic Dermatitis Eczema

Interventions

DRUG

EVO101

Topical Cream

Sponsors & Collaborators

  • Evommune, Inc.

    lead INDUSTRY

Principal Investigators

  • Eugene Bauer, MD · Evommune, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-27
Primary Completion
2023-07-27
Completion
2023-07-27
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05579899 on ClinicalTrials.gov